• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012

tetano

Editor, Senior Moderator
Vaccine. 2013 Jun 10. pii: S0264-410X(13)00725-1. doi: 10.1016/j.vaccine.2013.05.097. [Epub ahead of print]
Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.
Cort?s I, Camarero SP, Del Llano J, Pe?a LM, Hidalgo-Vega A.
Source

Instituto Max Weber, Majadahonda, Madrid, Spain.
Abstract
OBJECTIVE:

The objective of this survey was to describe the evolution of economic evaluation studies on vaccines available in Spain.
METHODS:

We conducted a systematic review of the economic evaluations published by Spanish researchers in major bibliographic databases available online from 1990 to 2012. For all references identified, we limited them to full economic evaluation carried out in Spanish vaccine programs. The following variables were analyzed: type of study, year of publication, vaccine evaluated, the herd immunity and the main methodological aspects proposed by international guidelines. The type of vaccines studied were Hepatitis A and B, Rotavirus, Influenza, Varicella, Tetanus, Measles, Human papillomavirus, Streptococcus pneumoniae infection and Neisseria meningitides serogroup C infection.
RESULTS:

A total of 34 references was included in the study. The number of economic evaluations has been increasing over the years by 86%. For many of the vaccines there were no economic evaluations, while others such as the vaccine against S. pneumoniae infection took up most of the studies. The non-vaccinated comparison was the most used strategy. The cost-effectiveness model was selected in 60% of cases. The most common health outcome was "cost per case prevented" and in 82% of the studies did not consider herd immunity. The results showed a cost-effectiveness ratio which was below breakeven.
CONCLUSIONS:

It is clear that the existence of a huge gap in this kind of work compared to other countries. Although the quality of the work discussed here was significant, we found many areas which could be improved. The reviewed literature exposed the great benefit of vaccination for society by analysing the health outcomes achieved for decades since its implementation. However, the evidence on the efficiency and effectiveness vaccination is not very high, and there are few studies about economic evaluation.

Copyright ? 2013 Elsevier Ltd. All rights reserved.

PMID:
23764534
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23764534
 
Back
Top Bottom